IGMS — IGM Biosciences Share Price
0.000.00%
Last trade - 00:00- $80.70m
- -$103.09m
- $2.68m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.68 | ||
| Price to Tang. Book | 1.68 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 30.12 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -91.45% | ||
| Return on Equity | -155.76% | ||
| Operating Margin | -7785.74% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 1.07 | 2.13 | 2.68 | 5.82 | 8.55 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
Directors
- Michael Loberg CHM (73)
- Fred Schwarzer PRE (69)
- Misbah Tahir CFO (46)
- Bruce Keyt CSO (68)
- Lisa Decker OTH (52)
- George Gauthier OTH (49)
- Chris Takimoto OTH
- Felix Baker IND (52)
- M. Kathleen Behrens IND (68)
- Julie Hambleton IND (63)
- Michael Lee IND (42)
- William Strohl IND (68)
- Christina Topsoe IND (40)
- Jakob Topsoe IND (52)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 13th, 2012
- Public Since
- September 18th, 2019
- No. of Shareholders
- 19
- No. of Employees
- 149
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 59,775,402
- Address
- 325 E Middlefield Rd, MOUNTAIN VIEW, 94043-4003
- Web
- https://igmbio.com/
- Phone
- +1 6509657873
- Auditors
- Deloitte & Touche LLP
Upcoming Events for IGMS
IGM Biosciences Inc Annual Shareholders Meeting
Q2 2025 IGM Biosciences Inc Earnings Release
Similar to IGMS
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the IGM Biosciences share price?
As of Today at 21:15 UTC, shares in IGM Biosciences are trading at $1.35. This share price information is delayed by 15 minutes.
How has the IGM Biosciences share price performed this year?
Shares in IGM Biosciences last closed at $1.35 and the price had moved by -85.68% over the past 365 days. In terms of relative price strength the IGM Biosciences share price has underperformed the S&P500 Index by -87.09% over the past year.
What are the analyst and broker recommendations for IGM Biosciences?
The overall consensus recommendation for IGM Biosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the IGM Biosciences dividend yield?
IGM Biosciences does not currently pay a dividend.
Does IGM Biosciences pay a dividend?
IGM Biosciences does not currently pay a dividend.
When does IGM Biosciences next pay dividends?
IGM Biosciences does not currently pay a dividend.
How do I buy IGM Biosciences shares?
To buy shares in IGM Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of IGM Biosciences?
As of the previous close price of $1.35, shares in IGM Biosciences had a market capitalisation of $80.70m.
Where are IGM Biosciences shares listed?
Here are the trading details for IGM Biosciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: IGMS
What kind of share is IGM Biosciences?
Based on an overall assessment of its quality, value and momentum IGM Biosciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a IGM Biosciences share price forecast for 2025?
The analyst consensus target price for shares in IGM Biosciences is $1.88. That is 39.26% above the last closing price of $1.35.
Analysts covering IGM Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$1.05 for the next financial year.
Find out moreWhat is the trend in the IGM Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IGM Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -91.64%.
As of the last closing price of $1.35, shares in IGM Biosciences were trading -82.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the IGM Biosciences PE Ratio?
The IGM Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of IGM Biosciences?
IGM Biosciences' management team is headed by:
- Michael Loberg - CHM
- Fred Schwarzer - PRE
- Misbah Tahir - CFO
- Bruce Keyt - CSO
- Lisa Decker - OTH
- George Gauthier - OTH
- Chris Takimoto - OTH
- Felix Baker - IND
- M. Kathleen Behrens - IND
- Julie Hambleton - IND
- Michael Lee - IND
- William Strohl - IND
- Christina Topsoe - IND
- Jakob Topsoe - IND